Wednesday, April 17, 2019
Monday, April 15, 2019
Mary Relling (St. Jude Children's Research Hospital) and I (Teri Klein) as Co-Principal Investigators of the Clinical Pharmacogenetics Implementation Consortium (CPIC) have been discussing the letter that the FDA recently sent to a genomics laboratory expressing concern that “providers may make inappropriate treatment decisions based” on pharmacogenetic testing offered by that lab. The FDA specifically highlighted that “the relationship between CYP2C19 genotype and drug response to escitalopram and sertraline is not established.”
While it is true that some pharmacogenomic testing laboratories may be including genetic variants in their tests, along with prescribing advice, that do not have adequate evidence for clinical utility, testing for variants in this particular gene does have utility for prescribing decisions for escitalopram and sertraline. In fact, CYP2C19 phenotypes are specifically included as actionable for these 2 drugs in CPIC’s Guideline for SSRIs.
Many CPIC guidelines encompass gene/drug pairs for which the mechanism of gene/drug association is pharmacokinetic in nature; therefore, gene-based dosing in these cases is analogous to medication dose adjustments that are routinely made on the basis of renal or hepatic function or due to drug-drug interactions, most of which are supported by mechanistic evidence rather than clinical trial data. The drug labels for both sertraline and escitalopram include recommendations for reduced dosages in hepatic impairment, based on similar mechanistic pharmacokinetic considerations as apply to CYP2C19 status, and presumably without randomized clinical trial-level “evidence.” Using genotype to evaluate CYP2C19 metabolism is certainly more relevant to hepatic metabolism of these agents than is using nonspecific clinical markers of “hepatic impairment.”
CPIC assigns an evidence level of A, B, C, or D to gene/drug pairs, with CPIC levels A and B deemed to have actionable prescribing based on genetics; importantly, gene/drug pairs with a CPIC level of C or D are not considered to have adequate evidence to support using a genetic test for prescribing, and this can serve as a useful starting point in deciding whether clinical genetic testing of that gene for that drug is likely to be justified.
In FDA’s warning letter, it is stated that “providers may make inappropriate treatment decisions based on these test results, including inappropriate dosing adjustments, prescribing an ineffective therapy, and not prescribing a therapy that could benefit the patient.” The same criticism could apply to any test result, even for the liver function tests that are already included in the FDA approved labels for these drugs. We agree that prescribers should be warned about the impact of hepatic function on drug effects; we advocate that pharmacokinetically based genetic tests may also be worthy of consideration by prescribers. Such a useful pharmacokinetically based genetic test includes use of CYP2C19 testing to assist with prescribing sertraline and escitalopram.